Old Drugs, New Targets: Molecular Docking Insights into Repurposing Proton Pump Inhibitors for the TLR4/MD-2, NLRP3, and C5aR1 Axes in Autoimmune Liver Diseases
Background/Objectives: Autoimmune liver diseases (AILDs), including autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, may include treatment-resistant cases and therefore require new therapeutic strategies. This in silico study evaluated proton pump inhibitors (PPIs) across three pat...